AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35248295 — intervention group
Group type: COMPARATOR
Intervention: arm cycle ergometer test (arm CET)
Number of subjects: 0
Study 32250279 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled patients in the PPI‐ePR system
Number of subjects: 2435
Study 32250279 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled doctors in the PPI‐ePR system
Number of subjects: 2435
Study 32250279 — intervention group
Group type: COMPARATOR
Intervention: Nonenrolled patients
Number of subjects: 2435
Study 32250279 — intervention group
Group type: COMPARATOR
Intervention: Nonenrolled doctors
Number of subjects: 2435
Study 32250279 — intervention group
Group type: COMPARATOR
Intervention: Patients and doctors surveyed
Number of subjects: 2435
Study 32250279 — intervention group
Group type: COMPARATOR
Intervention: PPI‐ePR system use
Number of subjects: 2435
Study 35981086 — intervention group
Group type: EXPERIMENTAL
Intervention: Koji-family.net 3-day program (KF3 PGM)
Number of subjects: 240
Study 35981086 — intervention group
Group type: COMPARATOR
Intervention: Usual services (Control)
Number of subjects: 240
Study 33567400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate treatment (100–400 mg/day)
Number of subjects: 49
Study 33567400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate treatment (150–400 mg/day)
Number of subjects: 49
Study 33567400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate treatment
Number of subjects: 49
Study 33070529 — intervention group
Group type: EXPERIMENTAL
Intervention: H63D gene variant in sporadic ALS group (16 cases, 13%)
Number of subjects: 124
Study 33070529 — intervention group
Group type: COMPARATOR
Intervention: H63D gene variant in healthy control group (8 cases, 4%)
Number of subjects: 124
Study 33070529 — intervention group
Group type: EXPERIMENTAL
Intervention: Allele level comparison of H63D gene variant
Number of subjects: 124
Study 34293411 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 2.5 mcg.mL‐1 (Group 1)
Number of subjects: 16
Study 34293411 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 5 mcg.mL‐1 (Group 2)
Number of subjects: 16
Study 33058835 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (150 mg)
Number of subjects: 139
Study 33058835 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 139
Study 36281113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to moderate intensity aerobic training (30 minutes daily)
Number of subjects: 37
Study 36281113 — intervention group
Group type: COMPARATOR
Intervention: Conventional customized physiotherapy (60 minutes daily)
Number of subjects: 37
Study 33625653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist interventions for drug-related problems (DRPs)
Number of subjects: 172
Study 32487558 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalculated height-adjusted total kidney volume (htTKV) excluding exophytic cysts
Number of subjects: 558
Study 32487558 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalculated htTKV
Number of subjects: 558
Study 32487558 — intervention group
Group type: COMPARATOR
Intervention: Original htTKV
Number of subjects: 558
Study 33731646 — intervention group
Group type: EXPERIMENTAL
Intervention: Free ROM Group (unlimited ROM)
Number of subjects: 60
Study 33731646 — intervention group
Group type: COMPARATOR
Intervention: Limited ROM Group (restricted to 90 degrees)
Number of subjects: 60
Study 35098958 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing high sn-2 palmitate for 16 weeks
Number of subjects: 102
Study 35098958 — intervention group
Group type: COMPARATOR
Intervention: Control formula using regular vegetable oil for 16 weeks
Number of subjects: 102
Study 35098958 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk for 16 weeks
Number of subjects: 102
Study 33726810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroscopic surgery (HA)
Number of subjects: 40
Study 33726810 — intervention group
Group type: COMPARATOR
Intervention: Personalised hip therapy (PHT)
Number of subjects: 40
Study 33726810 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised hip therapy (PHT) to Hip arthroscopic surgery (HA)
Number of subjects: 40
Study 33726810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HA and PHT
Number of subjects: 40
Study 35968501 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil combined with propofol (0.01‐0.03 μg/(kg·min) of sufentanil + 80‐100 μg/(kg·min) of propofol)
Number of subjects: 120
Study 35968501 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (3 μg/(kg·h) of fentanyl + 80‐100 μg/(kg·min) of propofol)
Number of subjects: 120
Study 34543871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vistusertib (75 mg/m2 BID on 2 days/week)
Number of subjects: 14
Study 34543871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vistusertib (30 mg/m2 BID on 3 days/week) combined with temozolomide (100 mg/m2/day) and topotecan (0.50 mg/m2/day)
Number of subjects: 14
Study 35457366 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness stress management intervention for 12 weeks
Number of subjects: 60
Study 35457366 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 34563187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan
Number of subjects: 15
Study 34563187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 32813780 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D atlas
Number of subjects: 62
Study 32813780 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional method combined with new technologies
Number of subjects: 62
Study 32813780 — intervention group
Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 62
Study 32813780 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 62
Study 35818342 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-assisted patient-initiated care (app intervention group)
Number of subjects: 103
Study 35818342 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 103
Study 32771267 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with music (TWM)
Number of subjects: 17
Study 32771267 — intervention group
Group type: COMPARATOR
Intervention: Training without music (TWtM)
Number of subjects: 17
Study 35795140 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) and fasting triglyceride glucose (TyG) used to create the CRP-TyG index (CTI).
Number of subjects: 5221
Study 34548368 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 800 mg/day
Number of subjects: 60
Study 34548368 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 400 mg/day
Number of subjects: 60
Study 34548368 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without clarithromycin
Number of subjects: 60
Study 35853583 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin use for induction
Number of subjects: 941
Study 34551168 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made meshes with cross-linked collagen membranes (Mesh+)
Number of subjects: 30
Study 34551168 — intervention group
Group type: COMPARATOR
Intervention: Custom-made meshes (Mesh-)
Number of subjects: 30
Study 33558285 — intervention group
Group type: EXPERIMENTAL
Intervention: Enisamium
Number of subjects: 0
Study 33558285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32335133 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (myIBDcoach)
Number of subjects: 909
Study 32335133 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 909
Study 34215452 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB‐FHbp booster dose administered 48 months after primary series
Number of subjects: 698
Study 34215452 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB‐FHbp primary vaccination
Number of subjects: 698
Study 34215452 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB‐FHbp booster dose
Number of subjects: 698
Study 34215452 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB‐FHbp vaccination
Number of subjects: 698
Study 32379374 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling followed by TCA 70%
Number of subjects: 32
Study 32379374 — intervention group
Group type: COMPARATOR
Intervention: Intraderma injection of 5-fluorouracil (5-FU)
Number of subjects: 32
Study 32713183 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone, 0.5 mg/kg (maximum dose 20 mg/day) qAM × 3 days postoperatively
Number of subjects: 1358
Study 32713183 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid group
Number of subjects: 1358
Study 33459540 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release betahistine (48 mg once daily)
Number of subjects: 264
Study 33459540 — intervention group
Group type: COMPARATOR
Intervention: Betaserc (24 mg twice daily)
Number of subjects: 264
Study 33459540 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 264
Study 32473901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept
Number of subjects: 55
Study 35869533 — intervention group
Group type: EXPERIMENTAL
Intervention: Empower-Autism programme plus treatment-as-usual
Number of subjects: 380
Study 35869533 — intervention group
Group type: COMPARATOR
Intervention: Usual local post-diagnostic offer plus treatment-as-usual
Number of subjects: 380
Study 33434444 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii‐Sports Boxing (Boxing)
Number of subjects: 28
Study 33434444 — intervention group
Group type: COMPARATOR
Intervention: Nintendo Wii Lego Star Wars (Lego)
Number of subjects: 28
Study 33434444 — intervention group
Group type: COMPARATOR
Intervention: Resting
Number of subjects: 28
Study 35833285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapilin
Number of subjects: 590
Study 35833285 — intervention group
Group type: COMPARATOR
Intervention: NovoRapid
Number of subjects: 590
Study 33966415 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-community integrated service model (HCISM) intervention
Number of subjects: 120
Study 33966415 — intervention group
Group type: COMPARATOR
Intervention: Routine intervention (Control group)
Number of subjects: 120
Study 33150681 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium, home-delivered meals
Number of subjects: 20
Study 33266039 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based parent intervention (4 weekly 30-min support calls)
Number of subjects: 394
Study 33266039 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based parent intervention
Number of subjects: 394
Study 33266039 — intervention group
Group type: COMPARATOR
Intervention: Control (printed materials)
Number of subjects: 394
Study 34311098 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) intervention consisting of 24 supervised exercise sessions over 12 weeks
Number of subjects: 90
Study 34311098 — intervention group
Group type: COMPARATOR
Intervention: Exercise educational materials (Control)
Number of subjects: 90
Study 36105267 — intervention group
Group type: EXPERIMENTAL
Intervention: START Together (experimental treatment)
Number of subjects: 20
Study 36105267 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 20
Study 32404775 — intervention group
Group type: EXPERIMENTAL
Intervention: AD providers
Number of subjects: 113
Study 32404775 — intervention group
Group type: COMPARATOR
Intervention: non-AD providers
Number of subjects: 113
Study 32404775 — intervention group
Group type: EXPERIMENTAL
Intervention: AD providers (baseline)
Number of subjects: 113
Study 35019078 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 J photobiomodulation (G7)
Number of subjects: 40
Study 35019078 — intervention group
Group type: COMPARATOR
Intervention: 1 J photobiomodulation (G1)
Number of subjects: 40
Study 35019078 — intervention group
Group type: COMPARATOR
Intervention: 4 J photobiomodulation (G4)
Number of subjects: 40
Study 35019078 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study 34537477 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation app
Number of subjects: 239
Study 34537477 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 239
Study 32647985 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anopexy (SA) with stapled line height (SLH) of 4.5 cm (group A)
Number of subjects: 119
Study 32647985 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anopexy (SA) with stapled line height (SLH) of 6 cm (group B)
Number of subjects: 119
Study 32647985 — intervention group
Group type: COMPARATOR
Intervention: Stapled anopexy (SA) with SLH of 4.5 cm (group A)
Number of subjects: 119
Study 32647985 — intervention group
Group type: COMPARATOR
Intervention: Stapled anopexy (SA) with SLH of 6 cm (group B)
Number of subjects: 119
Study 35109482 — intervention group
Group type: EXPERIMENTAL
Intervention: Our Family Journey (OFJ) program; culturally tailored, evidence-based skill-building program delivered over 4 weeks.
Number of subjects: 60
Study 35109482 — intervention group
Group type: COMPARATOR
Intervention: Written dementia caregiving information (control condition).
Number of subjects: 60
Study 34688369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (titrated to 45 mg)
Number of subjects: 204
Study 34688369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 34688369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 204
Study 36448932 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulclock (active group)
Number of subjects: 55
Study 36448932 — intervention group
Group type: COMPARATOR
Intervention: Masked group (control)
Number of subjects: 55
Study 33191484 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nomogram based on competing-risk regression model for predicting cancer-specific death (CSD).
Number of subjects: 1535
Study 33191484 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk classification system based on total nomogram scores.
Number of subjects: 1535
Study 32057131 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Imagery Training (FIT)
Number of subjects: 38
Study 32057131 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study 36299765 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lay health worker intervention including training, support, targeted care plan, case management, and financial subsidy
Number of subjects: 222
Study 36299765 — intervention group
Group type: COMPARATOR
Intervention: Usual care and health information on diabetes risk management
Number of subjects: 222
Study 33875799 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g/d of omega-3
Number of subjects: 138
Study 33875799 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 g/d of omega-3
Number of subjects: 138
Study 33875799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 34772616 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric neck strengthening exercises (3 times per week for 12 weeks)
Number of subjects: 40
Study 34772616 — intervention group
Group type: COMPARATOR
Intervention: Standard strength and conditioning program (control group)
Number of subjects: 40
Study 34880028 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month follow-up group (CT scan every 3 months)
Number of subjects: 886
Study 34880028 — intervention group
Group type: COMPARATOR
Intervention: 6-month follow-up group (CT scan every 6 months)
Number of subjects: 886
Study 34880028 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month follow-up group
Number of subjects: 886
Study 34880028 — intervention group
Group type: COMPARATOR
Intervention: 6-month follow-up group
Number of subjects: 886
Study 33211881 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with more egalitarian gender norm attitudes
Number of subjects: 4667
Study 33211881 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers in households receiving extra modules on sanitation and hygiene
Number of subjects: 4667
Study 33211881 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers experiencing time stress
Number of subjects: 4667
Study 33211881 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with greater social support
Number of subjects: 4667
Study 33211881 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers receiving extra complementary feeding modules
Number of subjects: 4667
Study 33211881 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed mothers
Number of subjects: 4667
Study 32667654 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine 2 mg transdermal patch for 1 week followed by a 4 mg patch for 23 weeks
Number of subjects: 94
Study 32667654 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal patch for 24 weeks
Number of subjects: 94
Study 32667654 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 94
Study 32667654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 34073163 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (RSV) supplementation for 30 days
Number of subjects: 48
Study 34073163 — intervention group
Group type: COMPARATOR
Intervention: Energy restriction (ER) for 30 days
Number of subjects: 48
Study 33371905 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol (two 200,000 IU drinking vials at once on the day of inclusion)
Number of subjects: 260
Study 33371905 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cholecalciferol (one 50,000 IU drinking vial on the day of inclusion)
Number of subjects: 260
Study 33371905 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol
Number of subjects: 260
Study 33371905 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cholecalciferol
Number of subjects: 260
Study 34952709 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm Stimulator
Number of subjects: 159
Study 34952709 — intervention group
Group type: COMPARATOR
Intervention: ShotBlocker
Number of subjects: 159
Study 34952709 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 159
Study 34160600 — intervention group
Group type: EXPERIMENTAL
Intervention: TYRX™ absorbable antibacterial envelope
Number of subjects: 0
Study 32437703 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic warning without efficacy information
Number of subjects: 1352
Study 32437703 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic warning with efficacy information
Number of subjects: 1352
Study 32437703 — intervention group
Group type: COMPARATOR
Intervention: Text-only warning without efficacy information
Number of subjects: 1352
Study 32437703 — intervention group
Group type: COMPARATOR
Intervention: Text-only warning with efficacy information
Number of subjects: 1352
Study 35996195 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus endovascular MMA embolization
Number of subjects: 154
Study 35996195 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 154
Study 33515175 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling activities (17 types)
Number of subjects: 799
Study 33515175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic gambling
Number of subjects: 799
Study 33515175 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for PPG
Number of subjects: 799
Study 33515175 — intervention group
Group type: EXPERIMENTAL
Intervention: Acculturation
Number of subjects: 799
Study 32339296 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncash incentives for blood donation
Number of subjects: 2229
Study 34954857 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg iv with vitamin D 1000 IU/d
Number of subjects: 48
Study 34954857 — intervention group
Group type: COMPARATOR
Intervention: Placebo with vitamin D 1000 IU/d
Number of subjects: 48
Study 33831216 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-intubated thoracic surgery
Number of subjects: 40
Study 33831216 — intervention group
Group type: COMPARATOR
Intervention: Intubated thoracic surgery
Number of subjects: 40
Study 34003735 — intervention group
Group type: EXPERIMENTAL
Intervention: Box simulator (with artificial nodules)
Number of subjects: 51
Study 34003735 — intervention group
Group type: COMPARATOR
Intervention: Fruit (banana)
Number of subjects: 51
Study 34003735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after using their assigned simulator
Number of subjects: 51
Study 34003735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups evaluated through OSCE
Number of subjects: 51
Study 33852722 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 37
Study 34181084 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp nerve blockade (B) and wound infiltration (I) with 0.25% bupivacaine, 1% lidocaine, and 1:200,000 epinephrine
Number of subjects: 141
Study 34181084 — intervention group
Group type: COMPARATOR
Intervention: Systemic analgesia (S) with 1 gram of paracetamol and 2 mg/kg ketoprofen administered IV after skin closure
Number of subjects: 141
Study 35803709 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based intervention
Number of subjects: 220
Study 33486139 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine infusion (APO)
Number of subjects: 84
Study 33486139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 616775801 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 group 1 (<1,200 ng/L)
Number of subjects: 8474
Study 616775801 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 group 3 (>1,800 ng/L)
Number of subjects: 8474
Study 616775801 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 levels
Number of subjects: 8474
Study 616775801 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15
Number of subjects: 8474
Study 34431989 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial envelope
Number of subjects: 1943
Study 34431989 — intervention group
Group type: COMPARATOR
Intervention: No antibacterial envelope
Number of subjects: 1943
Study 34058610 — intervention group
Group type: EXPERIMENTAL
Intervention: ImproveYourMood (monitoring and content; n = 62)
Number of subjects: 235
Study 34058610 — intervention group
Group type: EXPERIMENTAL
Intervention: ImproveYourMood+ (monitoring, content, and prompts; n = 60)
Number of subjects: 235
Study 34058610 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodTracker (monitoring-only; n = 58)
Number of subjects: 235